Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
SARS-CoV-2
T-cell responses
antibody responses
people with HIV
vaccination
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
13 01 2023
13 01 2023
Historique:
received:
18
05
2022
pubmed:
6
10
2022
medline:
18
1
2023
entrez:
5
10
2022
Statut:
ppublish
Résumé
People with human immunodeficiency virus (HIV) on antiretroviral therapy (ART) with good CD4 T-cell counts make effective immune responses following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are few data on longer term responses and the impact of a booster dose. Adults with HIV were enrolled into a single arm open label study. Two doses of ChAdOx1 nCoV-19 were followed 12 months later by a third heterologous vaccine dose. Participants had undetectable viraemia on ART and CD4 counts >350 cells/µL. Immune responses to the ancestral strain and variants of concern were measured by anti-spike immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA), MesoScale Discovery (MSD) anti-spike platform, ACE-2 inhibition, activation induced marker (AIM) assay, and T-cell proliferation. In total, 54 participants received 2 doses of ChAdOx1 nCoV-19. 43 received a third dose (42 with BNT162b2; 1 with mRNA-1273) 1 year after the first dose. After the third dose, total anti-SARS-CoV-2 spike IgG titers (MSD), ACE-2 inhibition, and IgG ELISA results were significantly higher compared to Day 182 titers (P < .0001 for all 3). SARS-CoV-2 specific CD4+ T-cell responses measured by AIM against SARS-CoV-2 S1 and S2 peptide pools were significantly increased after a third vaccine compared to 6 months after a first dose, with significant increases in proliferative CD4+ and CD8+ T-cell responses to SARS-CoV-2 S1 and S2 after boosting. Responses to Alpha, Beta, Gamma, and Delta variants were boosted, although to a lesser extent for Omicron. In PWH receiving a third vaccine dose, there were significant increases in B- and T-cell immunity, including to known variants of concern (VOCs).
Sections du résumé
BACKGROUND
People with human immunodeficiency virus (HIV) on antiretroviral therapy (ART) with good CD4 T-cell counts make effective immune responses following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are few data on longer term responses and the impact of a booster dose.
METHODS
Adults with HIV were enrolled into a single arm open label study. Two doses of ChAdOx1 nCoV-19 were followed 12 months later by a third heterologous vaccine dose. Participants had undetectable viraemia on ART and CD4 counts >350 cells/µL. Immune responses to the ancestral strain and variants of concern were measured by anti-spike immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA), MesoScale Discovery (MSD) anti-spike platform, ACE-2 inhibition, activation induced marker (AIM) assay, and T-cell proliferation.
FINDINGS
In total, 54 participants received 2 doses of ChAdOx1 nCoV-19. 43 received a third dose (42 with BNT162b2; 1 with mRNA-1273) 1 year after the first dose. After the third dose, total anti-SARS-CoV-2 spike IgG titers (MSD), ACE-2 inhibition, and IgG ELISA results were significantly higher compared to Day 182 titers (P < .0001 for all 3). SARS-CoV-2 specific CD4+ T-cell responses measured by AIM against SARS-CoV-2 S1 and S2 peptide pools were significantly increased after a third vaccine compared to 6 months after a first dose, with significant increases in proliferative CD4+ and CD8+ T-cell responses to SARS-CoV-2 S1 and S2 after boosting. Responses to Alpha, Beta, Gamma, and Delta variants were boosted, although to a lesser extent for Omicron.
CONCLUSIONS
In PWH receiving a third vaccine dose, there were significant increases in B- and T-cell immunity, including to known variants of concern (VOCs).
Identifiants
pubmed: 36196614
pii: 6748267
doi: 10.1093/cid/ciac796
pmc: PMC9619587
doi:
Substances chimiques
ChAdOx1 nCoV-19
B5S3K2V0G8
BNT162 Vaccine
0
Immunoglobulin G
0
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
201-209Subventions
Organisme : Medical Research Council
ID : MC_UU_00004/04
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L00528X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L006588/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 403193363
Pays : United Kingdom
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
JAMA Netw Open. 2021 Feb 1;4(2):e2037069
pubmed: 33533933
Cell. 2022 Feb 3;185(3):467-484.e15
pubmed: 35081335
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
Postgrad Med J. 2022 May 1;98(1159):389-394
pubmed: 37066438
PLoS Pathog. 2012 Feb;8(2):e1002464
pubmed: 22363214
Nat Med. 2021 Feb;27(2):279-288
pubmed: 33335322
Am J Respir Crit Care Med. 2011 Feb 1;183(3):388-95
pubmed: 20851926
J Exp Med. 2018 Jun 4;215(6):1571-1588
pubmed: 29739835
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
Immunity. 2021 Dec 14;54(12):2681-2687
pubmed: 34910934
Lancet. 2021 Dec 19;396(10267):1979-1993
pubmed: 33220855
Lancet HIV. 2021 Aug;8(8):e474-e485
pubmed: 34153264
Semin Respir Crit Care Med. 2016 Apr;37(2):267-76
pubmed: 26974303
Lancet. 2021 Mar 6;397(10277):881-891
pubmed: 33617777
Cell. 2021 May 27;184(11):2939-2954.e9
pubmed: 33852911
AIDS. 2021 Mar 15;35(4):F1-F10
pubmed: 33587448
Nat Med. 2021 Feb;27(2):270-278
pubmed: 33335323
Lancet. 2021 Dec 18;398(10318):2258-2276
pubmed: 34863358
Blood Rev. 2022 Jul;54:100931
pubmed: 35120771
Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
Emerg Microbes Infect. 2021 Dec;10(1):629-637
pubmed: 33691606
Clin Infect Dis. 2007 Nov 1;45(9):1214-20
pubmed: 17918087
Lancet Microbe. 2022 Jan;3(1):e4-e5
pubmed: 34901896
Cell. 2021 Jan 7;184(1):64-75.e11
pubmed: 33275900
Nat Commun. 2021 Apr 6;12(1):2055
pubmed: 33824342
Lancet. 2021 Jul 10;398(10295):121-130
pubmed: 34181880
AIDS. 2022 Oct 1;36(12):F7-F16
pubmed: 35866847
Nat Med. 2021 Jun;27(6):1062-1070
pubmed: 33888900
Lancet. 2021 Sep 4;398(10303):856-869
pubmed: 34370971
JCI Insight. 2022 Apr 8;7(7):
pubmed: 35192543
Science. 2022 May 6;376(6593):eabn4947
pubmed: 35289632
Clin Infect Dis. 2011 Jan 15;52(2):219-27
pubmed: 21288848
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
Cell Rep Med. 2021 Feb 22;2(3):100207
pubmed: 33763653
Lancet. 2021 Dec 11;398(10317):2126-2128
pubmed: 34871545
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Science. 2020 Dec 18;370(6523):1464-1468
pubmed: 33184236
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
Lancet. 2021 Sep 11;398(10304):981-990
pubmed: 34480858
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381
Cell. 2022 Feb 17;185(4):603-613.e15
pubmed: 35026152
Science. 2021 Sep 17;373(6561):1372-1377
pubmed: 34385356